Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
If you are researching cancer immune cell therapy, you may have come across the term immune surveillance. It sounds technical, but the idea is simple, and it explains why researchers became interested in natural killer (NK) cells in the first place. This article explains what immune surveillance is, how NK cells fit into it, and what that does and does not tell you about NK cell therapy offered in Osaka, Japan.
The short answer
Immune surveillance is the body’s routine process of finding and removing abnormal cells, including cells that could develop into cancer. NK cells are one of the immune cell types involved. NK cell therapy is built on this idea: cells collected from your own blood are activated and expanded outside the body, then returned by intravenous infusion, with the aim of reinforcing immune function. It is not a guaranteed treatment, and it is not a replacement for standard cancer care. Whether it is appropriate for you has to be decided in a medical consultation.
What is immune surveillance?
Even in healthy people, abnormal cells are thought to arise in the body from time to time. Most of them never become a problem, because immune cells detect and eliminate them early. This ongoing patrol is called immune surveillance. When it works well, abnormal cells are removed before they can multiply.
Researchers believe that when this surveillance weakens, abnormal cells may be more likely to slip through and grow. Factors that are thought to be associated with lower immune activity include advancing age, ongoing stress, and the effects of cancer itself. This is a general scientific concept rather than a prediction about any individual person, and it does not mean that cancer is caused by a single failure of the immune system.
Where do NK cells fit in?
NK cells are a type of lymphocyte that circulates in the blood. Their defining feature is that they can recognize and attack certain abnormal cells, such as cancer cells and virus-infected cells, without waiting for instructions from other immune cells. This is why they are described as part of the innate immune system, the body’s first line of defense.
In laboratory and clinical research, NK cell activity has been studied in relation to cancer, and NK cells are known to release molecules such as perforin that damage target cells. At the same time, cancer cells can find ways to escape immune detection, so research results should not be generalized. A finding in a laboratory or a single study does not automatically translate into a benefit for every patient.
How does NK cell therapy relate to immune surveillance?
NK cell therapy takes the idea of immune surveillance and asks whether the number and activity of NK cells can be supported from outside the body. At Grand Green Osaka Umekita Clinic, the therapy involves drawing a blood sample, activating and expanding NK cells at a specialized cell processing facility, and returning the cells to the patient by intravenous infusion. Treatment is outpatient, so patients do not need to be hospitalized.
Because the cells come from the patient, this is called an autologous therapy. In Japan, it is provided under a regenerative medicine provision plan submitted to and accepted by the authorities under the Act on the Safety of Regenerative Medicine. Temporary effects such as fever or fatigue can occur, and individual responses vary. The therapy is not intended to replace surgery, chemotherapy, or radiation therapy. It may be considered alongside them, and the clinic can coordinate with the institution providing your standard treatment.
It is also worth remembering that the immune system is complex. NK cells work alongside other immune cells, and the tumor environment can suppress immune activity in ways that are still being studied. For this reason, returning more NK cells to the body is a reasonable concept to explore, but it should not be read as a promise of any particular outcome. Your doctor can explain how the available evidence applies, or does not apply, to your situation.
Questions to ask before you decide
Understanding the science is useful, but a decision about treatment depends on your own medical situation. The following questions can help you prepare for a consultation.
- What is my current diagnosis and stage, and what does my primary oncologist recommend as standard treatment?
- Is NK cell therapy suitable for my condition, and are there situations in which it would not be recommended?
- What are the possible side effects, and how are they monitored during and after treatment?
- How many sessions are usually planned, over what period, and what is the total cost?
- What are the limits of the therapy, and what evidence is currently available for my type of cancer?
- How will the clinic share information with my doctor at home or in my own country?
NK cell therapy is a self-pay treatment in Japan and is not covered by national health insurance. Costs, the number of treatments, risks, side effects, and eligibility are confirmed at a consultation with a doctor, and the clinic’s information pages describe the flow and fees in more detail.
Consulting in Osaka as an international patient
Grand Green Osaka Umekita Clinic is located in Umeda, Osaka, and provides information pages for international patients, including an English-language page for NK cell therapy. If you are living in Japan or considering traveling for treatment, it is worth preparing your medical records and a list of questions in advance, and discussing your plan with your current oncologist.
Immune surveillance is a helpful way to understand why NK cells attract attention, but it is only a starting point. A careful, individual discussion with a doctor is what determines whether this option makes sense for you.
- Immune surveillanceRoutine patrol for abnormal cells
- NK cellsInnate immune cells
- Cells returned by IVYour own expanded NK cells
- Doctor consultationSuitability confirmed first
This diagram is a conceptual summary of the article content
References
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.